ARGENX SE AND THE BANK OF NEW YORK MELLON As Depositary AND OWNERS AND HOLDERS OF AMERICAN DEPOSITARY SHARES Deposit AgreementDeposit Agreement • May 16th, 2017 • Argenx Se • Biological products, (no disgnostic substances) • New York
DEPOSIT AGREEMENT dated as of , 2017 among ARGENX SE, a company incorporated under the laws of The Netherlands (herein called the Company), THE BANK OF NEW YORK MELLON, a New York banking corporation (herein called the Depositary), and all Owners and Holders (each as hereinafter defined) from time to time of American Depositary Shares issued hereunder.
INDEMNIFICATION AGREEMENTIndemnification Agreement • April 21st, 2017 • Argenx N.V • Biological products, (no disgnostic substances)
ARGENX SE 3,125,000 Ordinary Shares (including 1,608,000 American Depositary Shares, each Representing One Ordinary Share) UNDERWRITING AGREEMENTUnderwriting Agreement • February 4th, 2021 • Argenx Se • Biological products, (no disgnostic substances) • New York
ASSET PURCHASE AGREEMENTAsset Purchase Agreement • November 30th, 2022 • Argenx Se • Biological products, (no disgnostic substances) • Massachusetts
This ASSET PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of November 29, 2022 (the “Effective Date”), by and between Bluebird Bio, Inc., a corporation organized under the laws of Delaware (“Seller”), and ARGENX BV, a limited liability company organized under the laws of Belgium (“Buyer”). Buyer and Seller may hereinafter be referred to individually as a “Party” and collectively as the “Parties”.
ARGENX SE 3,658,515 Ordinary Shares (including 2,584,138 American Depositary Shares, each Representing One Ordinary Share) UNDERWRITING AGREEMENTUnderwriting Agreement • May 29th, 2020 • Argenx Se • Biological products, (no disgnostic substances) • New York
ARGENX SE 2,244,899 Ordinary Shares (including 1,580,981 American Depositary Shares, each Representing One Ordinary Share) UNDERWRITING AGREEMENTUnderwriting Agreement • July 21st, 2023 • Argenx Se • Biological products, (no disgnostic substances) • New York
Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. COLLABORATION AND LICENSE AGREEMENT between ARGENX BV and ZAI AUTO IMMUNE (HONG...Collaboration and License Agreement • March 30th, 2021 • Argenx Se • Biological products, (no disgnostic substances) • New York
This Collaboration and License Agreement (the “Agreement”) is made and entered into effective as of 6 January 2021 (the “Effective Date”) by and between argenx BV, a private limited company organized under the laws of Belgium with its principal place of business at Industriepark Zwijnaarde 7, 9052 Zwijnaarde (Ghent), Belgium (“Licensor”), and Zai Auto Immune (Hong Kong) Limited, a Hong Kong company, with an address at Room 2301, 23F, Island Place Tower, 510 King’s Road, North Point, Hong Kong (“Licensee”) and, solely with respect to Section 15.16 Zai Lab Limited, a China company, with an address at 4F, Bldg 1, Jinchuang Plaza 4560 Jinke Rd Shanghai, China, 201210 (“Parent”). Licensor and Licensee are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
SERVICE AGREEMENT between Bio-Incubator Gent 2 NV and argenx bvbaAgreement • April 21st, 2017 • Argenx N.V • Biological products, (no disgnostic substances)
The Service Provider and the Service Receiver are hereinafter referred to jointly as the “Parties” and individually also as a “Party”.
CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[...***...].” A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE U.S. SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION...Patent License Agreement • April 21st, 2017 • Argenx N.V • Biological products, (no disgnostic substances) • Texas
This Patent License Agreement (“Agreement”) is between The Board of Regents of The University of Texas System, an agency of the State of Texas, whose address is 201 West 7th Street, Austin, Texas 78701, on behalf of The University of Texas Southwestern Medical Center, a component institution of The University of Texas System (“Licensor”) and arGEN-X BV, a Dutch corporation, with its principal place of business at Dr Molewaterplein 50, 3015 GE Rotterdam, The Netherlands (“Licensee”) (collectively, “Parties”, or singly, “Party”).
ARGENX SE 3,475,000 American Depositary Shares, each Representing One Ordinary Share UNDERWRITING AGREEMENTUnderwriting Agreement • September 20th, 2018 • Argenx Se • Biological products, (no disgnostic substances) • New York
COLLABORATION AND LICENSE AGREEMENT BY AND AMONG ARGENX BVBA AND ARGENX SE (SOLELY FOR PURPOSES OF SECTIONS 16.2 AND 16.3) AND CILAG GMBH INTERNATIONALCollaboration and License Agreement • March 26th, 2019 • Argenx Se • Biological products, (no disgnostic substances) • New York
This Collaboration and License Agreement (the “Agreement”) is made and effective as of December 2, 2018 (the “Execution Date”) by and between argenx BVBA, a Belgian company (“argenx”) and, solely for purposes of Sections 16.2 and 16.3, argenx SE, a Societas Europaea (“Parent”), on the one hand, and Cilag GmbH International, a Swiss company (“Janssen”), on the other hand.
ASSET PURCHASE AGREEMENT BY AND BETWEEN BAYER HEALTHCARE PHARMACEUTICALS INC. AND ARGENX BV November 20, 2020Asset Purchase Agreement • November 23rd, 2020 • Argenx Se • Biological products, (no disgnostic substances) • New York
This ASSET PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of November 20, 2020 (the “Effective Date”), by and between ARGENX BV, a limited liability company organized under the laws of Belgium and having its registered address at Industriepark Zwijnaarde 7, 9052 Zwijnaarde, Belgium (“Buyer”), and BAYER HEALTHCARE PHARMACEUTICALS INC., a company incorporated under the laws of Delaware and having its registered address at 100 Bayer Blvd, Whippany, NJ 07981 (“Seller”). Buyer and Seller may hereinafter be referred to individually as a “Party” and collectively as the “Parties”.
UNDERWRITING AGREEMENTUnderwriting Agreement • December 11th, 2017 • Argenx Se • Biological products, (no disgnostic substances) • New York
INVESTMENT AGREEMENT Between argenx SE and Johnson & Johnson Innovation – JJDC, Inc. (the Agreement)Investment Agreement • March 26th, 2019 • Argenx Se • Biological products, (no disgnostic substances)
Admission means the admission to trading of the Investment Securities on the regulated market Euronext Brussels organised by Euronext Brussels NV/SA;
